Novo Nordisk ROA 2006-2018 | NVO

Current and historical return on assets (ROA) values for Novo Nordisk (NVO) over the last 10 years.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $92.940B $16.962B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $337.858B 16.72
Pfizer (PFE) United States $223.411B 13.75
Novartis AG (NVS) Switzerland $182.569B 15.82
Merck (MRK) United States $169.563B 15.15
AbbVie (ABBV) United States $153.340B 15.64
Sanofi (SNY) France $105.164B 13.31
GlaxoSmithKline (GSK) United Kingdom $103.492B 14.15
Eli Lilly (LLY) United States $97.374B 19.33
AstraZeneca (AZN) United Kingdom $94.122B 9.86
Bristol-Myers Squibb (BMY) United States $92.940B 18.28